BioPlus (099430) Financial Statements

OverviewFinancialsChecksFilings

In fiscal year 2025, BioPlus (099430) reported revenue of 90.9 billion KRW.

Income Statement

YearRevenueOp ProfitNet IncomeSource
202590.9 billion KRW15.0 billion KRW20.0 billion KRW[source]
202466.4 billion KRW23.7 billion KRW17.5 billion KRW[source]
202365.0 billion KRW28.0 billion KRW27.4 billion KRW[source]
202256.7 billion KRW25.3 billion KRW20.7 billion KRW[source]
202137.4 billion KRW18.2 billion KRW10.7 billion KRW[source]

Balance Sheet

YearTotal AssetsTotal LiabilitiesTotal EquitySource
2025253.7 billion KRW78.5 billion KRW175.1 billion KRW[source]
2024241.8 billion KRW107.0 billion KRW134.7 billion KRW[source]
2023160.8 billion KRW30.3 billion KRW130.5 billion KRW[source]
2022146.0 billion KRW31.4 billion KRW114.6 billion KRW[source]
202186.7 billion KRW7.9 billion KRW78.8 billion KRW[source]
Financials & Filings: DART (traceable by receipt number) · Prices: Financial Services Commission · Data Sources · Last checked: 2026-08-29 · About · Delisting market cap threshold: KOSPI 5B KRW / KOSDAQ 4B KRW (per listing rules) · This page provides factual information, not investment advice